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a b s t r a c t 
N 6 -isopentenyladenosine (i 6 A), a naturally occurring modiﬁed nucleoside, inhibits the proliferation of hu- 
man tumor cell lines in vitro , but its mechanism of action remains unclear. Treatment of MCF7 human breast
adenocarcinoma cells with i 6 A or with three synthetic analogs (allyl 6 A, benzyl 6 A, and butyl 6 A) inhibited 
growth and altered gene expression. About 60% of the genes that were differentially expressed in response 
to i 6 A treatment were also modulated by the analogs, and pathway enrichment analysis identiﬁed the 
NRF2-mediated oxidative stress response as being signiﬁcantly modulated by all four compounds. Luciferase 
reporter gene assays in transfected MCF7 cells conﬁrmed that i 6 A activates the transcription factor NRF2. 
Assays for cellular production of reactive oxygen species indicated that i 6 A and analogs had antioxidant ef- 
fects, reducing basal levels and inhibiting the H 2 O 2 - or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced 
production in MCF7 or dHL-60 (HL-60 cells induced to differentiate along the neutrophilic lineage) cell lines, 
respectively. In vivo , topical application of i 6 A or benzyl 6 A to mouse ears prior to TPA stimulation lessened
the inﬂammatory response and signiﬁcantly reduced the number of inﬁltrating neutrophils. These results 
suggest that i 6 A and analogs trigger a cellular response against oxidative stress and open the possibility of
i 6 A and benzyl 6 A being used as topical anti-inﬂammatory drugs. 
c © 2014 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license 
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). ntroduction 
The enzyme tRNA-isopentenyltransferase-1 (E.C. 2.5.1.75), en- 
oded by the putative tumor suppressor gene TRIT1 [ 1 ], catalyzes 
he transfer of an isopentenyl group from isopentenyl diphosphate to 
he adenosine in position 37 of selenocysteine-speciﬁc transfer RNA 
tRNA) [ 2 , 3 ]. The resulting isopentenyladenosine-tRNA (i 6 A-tRNA) 
mproves the reading frame maintenance during the synthesis of se- 
enoproteins [ 4 ]. N 6 -isopentenyladenosine (i 6 A), which is a break- 
own product of i 6 A-tRNA turnover, is found in mammalian cells and 
s excreted in the urine [ 5 , 6 ]. 
As a modiﬁed nucleoside, i 6 A has been investigated from late six- 
ies of last century for its effects on the inhibition of cell replication in Abbreviations: allyl 6 A, N6-allyladenosine; benzyl 6 A, N6-benzyladenosine; butyl 6 A, 
6-butyladenosine; i 6 A, N6-isopentenyladenosine. 
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ttp://dx.doi.org/10.1016/j.redox.2014.03.001 different cancer cell lines [ 7 ]. These early works led to the study of its 
potential use as a natural antitumor drug in humans [ 8 ] and animal 
models [ 9 ]. Despite initial enthusiasm, the pilot clinical trial did not 
lead to convincing conclusions about therapeutic applications of i 6 A 
as an antitumor agent [ 10 ] and the molecule had only slight effects, 
if any, on tumor growth in rodents [ 9 ]. More recently, we did not 
observe any antitumor activity of i 6 A when injected intraperitoneally 
into Swiss nude mice bearing ascites of human ovarian cancer IGROV1 
cells [ 11 ]. Only Laezza et al. reported that growth of a xenograft rat 
tumor, in nude mice, was inhibited after the subcutaneous injection 
of i 6 A directly at the tumor site [ 12 ]. These results, together with a 
growing body of evidence that i 6 A had antiproliferative effects in cell 
culture [ 13 –15 ], suggested that i 6 A was ineffective in vivo as an anti- 
cancer agent because it was rapidly metabolized, as suggested in [ 16 ], 
becoming ineffective. 
Based on biochemical research using cultured cells, different 
mechanisms of action for i 6 A have been suggested, including induc- 
tion of apoptosis [ 14 , 17 ], inhibition of cell proliferation [ 15 , 18 ] or open access article under the CC BY-NC-ND license ( http: // creativecommons.org / 
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1 http: // linus.nci.nih.gov / BRB-ArrayTools.html . 
2 http: // www.ingenuity.com . 
3 http: // www.ingenuity.com / wp-content / themes / ingenuitytheme / pdf / ipa / 
functions-pathways-pval-whitepaper.pdf . protein prenylation [ 12 ], and activation of the A3 adenosine recep-
tor [ 19 ]. Using a different approach, gene expression analysis of i 6 A-
treated MCF7 and A549 cells (from human breast adenocarcinoma
and lung carcinoma, respectively), we found that the inhibitory ef-
fects of this compound were associated with the induction of several
genes known to be activated during cell cycle arrest in response to
stress [ 11 ]. Nonetheless, the precise mechanism by which i 6 A inhibits
cancer cell growth remains unclear. 
To help elucidate the mechanism of action of i 6 A, we previously
synthesized and tested in vitro a large group of i 6 A analogs with N 6 -
modiﬁcations [ 20 ]. Three compounds, namely allyl 6 A, benzyl 6 A, and
butyl 6 A (with an allyl, benzyl, or butyl group, respectively, replacing
the N 6 -isopentenyl group), strongly inhibited the proliferation of hu-
man T24 bladder cancer cells. The present study was conducted to
determine if i 6 A and these three analogs exerted their cellular effects
by acting on a common molecular pathway, in order to better under-
stand their mechanism of action and to shed light on i 6 A involvement
in the stress response, as suggested by our earlier study [ 11 ]. To this
aim, we analyzed the transcriptomes of MCF7 cells treated (or not)
with i 6 A or its analogs and used Ingenuity Pathways Analysis to iden-
tify the molecular pathways in which gene expression levels were
most signiﬁcantly altered. 
Herein we show that i 6 A and its analogs altered the expression lev-
els of genes involved in the NRF2-mediated oxidative stress response.
The compounds directly activated the NRF2 transcription factor, lead-
ing to a cellular response against external oxidative stress stimuli,
speciﬁcally H 2 O 2 and 12-O-tetradecanoyl phorbol-13-acetate (TPA),
in MCF7 cells and in the promyelocytic leukemia HL-60 cell line (dif-
ferentiated to neutrophil lineage), respectively. Additionally, two of
the studied compounds—i 6 A and benzyl 6 A—exhibited in vivo anti-
inﬂammatory activity, when topically applied to the skin in a Car-S
mouse model of TPA-induced oxidative stress leading to inﬂamma-
tion. 
Material and methods 
Cell lines, nucleosides and animals 
Human breast adenocarcinoma MCF7 and promyelocytic leukemia
HL-60 cell lines were purchased from the American Type Culture Col-
lection (ATCC-LGC Standards, Teddington, UK) and propagated in the
recommended culture media. HL-60 cells were induced to differenti-
ate (dHL-60) along the neutrophilic lineage by culturing with 1.25%
DMSO (Sigma-Aldrich, St. Louis, USA) for one week [ 21 ]. 
i 6 A and N 6 -benzyladenosine (benzyl 6 A) were purchased from
OlChemIm (Olomouc, Czech Republic). We synthesized N 6 -
allyladenosine (allyl 6 A) and N 6 -butyladenosine (butyl 6 A) as de-
scribed [ 20 ]. Puriﬁed compounds were analyzed by 500-MHz 1H NMR
to conﬁrm the assigned structures and purity ( ≥ 99%). 
Female Car-S mice [ 22 ] aged 8–12 weeks were used in ear in-
ﬂammation assays. All animals received humane care according to
the criteria outlined in the “Guide for the Care and Use of Labora-
tory Animals” [ 23 ]. The study protocol was approved by the Ethics
Committee for Animal Experimentation of Casaccia Research Center,
ENEA, where the in vivo study was conducted. 
Cell viability assay 
MCF7 cells were plated at 700 cells per well in 96-well plates
in culture medium containing resazurin (AlamarBlue 
®
; Invitro-
gen; Life Technologies Italia, Monza, Italy; diluted according to the
manufacturer ’ s instructions) and left to attach for 6 h. Then, to some
wells, i 6 A or an analog was added to a ﬁnal concentration of 10 μM (4
replicates per condition) and the cells were cultured for 4 days. Cell
growth was determined from the metabolic conversion of resazurin
into the ﬂuorescent resoruﬁn (excitation 535 nm, emission 590 nm)measured using an Ultra multiplate reader (Tecan Group, Mannedorf /
Zurich, Switzerland). 
For the dose–response experiment, cells were cultured for 4 days
in the presence of the compounds at 0, 1, 3, 9, 27 or 81 μM. Each
compound was tested at each concentration in six replicates. The
concentrations at which the i 6 A analogs inhibited growth to the same
extent as 10 μM i 6 A, i.e. equi-effective doses, were determined from
the dose–response curves. 
RNA extraction and microarray gene expression analysis 
MCF7 cells were treated for 6 h with equi-effective doses of the
nucleosides or left untreated (4 replicates per condition). Total RNA
was extracted using Trizol Plus RNA Puriﬁcation Kit (Invitrogen, Carls-
bad, CA, USA), treated with deoxyribonuclease I (ampliﬁcation grade,
Invitrogen) and puriﬁed with RNeasy MinElute Cleanup kit (Qiagen,
Hilden, Germany). The integrity of the RNA was veriﬁed using the RNA
Nano Assay Kit on the 2100 Bioanalyzer microﬂuidics-based platform
(Agilent Technologies, Santa Clara, CA, USA); all samples were deter-
mined to be of good quality, having an RNA integrity number > 9. 
Total RNA (500 ng) was used to synthesize biotinylated cRNA using
the RNA Ampliﬁcation Kit (Ambion, Austin, TX, USA). cRNA (1500 ng)
was hybridized for 18 h to HumanHT-12 Expression BeadChips (Illu-
mina, San Diego, CA, USA) according to the manufacturer ’ s protocol.
Fluorescence intensities were acquired with a BeadArray Reader (Il-
lumina). Using BeadStudio v. 3 software, the dataset was normalized
using a cubic spline algorithm, and a detection P -value < 0.05 was
set as a cut-off to select reliable expression data. After this quality
control ﬁltering, we used probes with a coefﬁcient of variation > 0.15
( n = 3286) for the subsequent analyses, in order to consider a smaller
but more informative number of probes. 
Unsupervised clustering and class comparison analyses of samples
according to their gene expression proﬁles were done using BRB Ar-
rayTools developed by Richard Simon and Amy Peng Lam 1 . Gene lists
were generated by pair-wise comparison of untreated cells with cells
treated with each of the four compounds. Genes that were differen-
tially expressed between untreated and treated cells were identiﬁed
using random variance t statistics [ 24 ]. Venn diagrams were drawn
using Venny [ 25 ]. 
Pathway enrichment analysis of gene lists (containing genes dif-
ferentially expressed at P < 1.0 × 10 −4 and with fold-change ≥1.5)
was performed using Ingenuity Pathway Analysis software (Ingenuity
Systems, Redwood City, CA, USA) 2 to identify the canonical pathways
modulated by treatment with i 6 A and its analogs. The four gene lists,
containing gene symbols, fold-change, and P -values, were uploaded
and the IPA Core Analysis was carried out using default settings. The
resulting four datasets were then subject to Compare Analysis, car-
ried out using default settings. Our attention was focused on the
results obtained in the Canonical Pathways section, which showed
the pathways that were most signiﬁcantly altered across the four
datasets. Pathway enrichment (i.e. statistically signiﬁcant association
between genes in our lists and pathways of the IPA knowledge base)
was assessed using a right-tailed Fisher ’ s exact test and Benjamini–
Hochberg multiple testing correction [ 26 ] 3 . In particular, the number
of genes in our dataset and the total number of the genes annotated in
each pathway of the IPA knowledge base were taken into account to
calculate a P -value that referred to the over-representation of genes
in a given pathway. Therefore, enriched pathways are those having
more genes belonging to our datasets than expected by chance. 
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fuantitative real-time PCR 
Microarray results were validated by quantitative real-time PCR 
n 6 genes that were differentially expressed ( P < 0.0001) in i 6 A-, 
llyl 6 A-, benzyl 6 A-, and butyl 6 A- treated cells ( ATF3 , CXCR7 , HMOX1 , 
GDCC3 , OSGIN1 and PPP1R3C ) and on another 3 genes ( DNAJB9 , HBP1 
nd PPP1R15A ) that were previously shown to be modulated by i 6 A 
reatment [ 11 ] and that here too were differentially expressed. Tran- 
cript levels of NFE2L2 gene were measured because of its involve- 
ent in the main i 6 A-affected pathway. Total RNA (1 μg) from un- 
reated and nucleoside-treated cells, prepared as above, was reverse- 
ranscribed using a 1:1 mixture of oligo(dT) 18 and random hex- 
mer primers, according to the protocol given in the Transcriptor 
irst Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, 
ermany). cDNA ( ˜ 25 ng) was ampliﬁed in a 20 μl reaction volume 
ontaining 10 μl 2 × Fast SYBR Green Master Mix (Applied Biosys- 
ems, Foster City, CA, USA) and 0.3 μM exon-spanning PCR primers 
 Supplementary Table 1 ). Reactions were run in duplicate on the 
900HT real-time PCR system (Applied Biosystems). Expression levels 
ere normalized to those of human hypoxanthine phosphoribosyl- 
ransferase 1 ( HPRT1 ) gene. Relative quantities (RQ) in mRNA levels, 
ith respect to a pool of RNA from untreated cells (used as calibrator), 
ere assessed using the comparative cycle threshold (Ct) method. 
nalysis of NRF2 signaling activity 
The transcriptional activity of NRF2 at antioxidant response el- 
ments was measured using the Cignal Antioxidant Response Re- 
orter (luc) kit (SABiosciences, Qiagen). Brieﬂy, MCF7 cells were tran- 
iently transfected in 48-well plates with an NRF2-responsive ﬁreﬂy 
uciferase reporter plasmid and a control plasmid constitutively ex- 
ressing Renilla luciferase (SABiosciences, Qiagen) in the presence 
f 1 μl FuGene HD transfection reagent (Promega), according to the 
anufacturer ’ s instructions. After 24 h, cells were treated with 10 μM 
 
6 A for 6 h or left untreated. Luciferase was assayed using the Dual- 
uciferase Reporter Assay System (Promega). Fireﬂy luciferase signals 
ere normalized to those of Renilla luciferase to control for transfec- 
ion efﬁciency. Luminescence was measured on a Glomax 
®
20 / 20 
uminometer (Promega). Six independent transfections were carried 
ut in the luciferase assay. 
OS and superoxide anion assays 
To measure the effects of i 6 A on basal ROS production, MCF7 cells 
ere ﬁrst treated with 1, 10 or 100 μM i 6 A for 6 h in complete 
edium and then loaded with 2 ′ ,7 ′ -dichlorodihydroﬂuorescein diac- 
tate (H 2 DCFDA, Life Technologies Italia, Monza, Italy) by incubating 
hem with the indicator at 10 μM in PBS for 30 min. Instead, to mea- 
ure the ability of i 6 A to inhibit ROS production induced by H 2 O 2 
reatment, MCF7 cells were pretreated with i 6 A (dose–response ex- 
eriment: 1, 10, 100 μM i 6 A for 6 h; time-course experiment: 10 μM 
 
6 A for 1, 2, 6, 24 or 30 h), then loaded with H 2 DCFDA as above and
nally stimulated to produce ROS with 1 mM H 2 O 2 in PBS for 15 min. 
o test the effects of i 6 A analogs, cells were pretreated for 6 h with 
qui-effective concentrations of allyl 6 A, benzyl 6 A, and butyl 6 A prior 
o H 2 DCFDA labeling and H 2 O 2 treatment. After the treatments, cells 
ere washed with PBS and the ﬂuorescence produced by the oxidized 
erivative of H 2 DCFDA, proportional to the quantity of ROS in the cells, 
as measured using an Ultra multiplate reader (Tecan Group; excita- 
ion, 485 nm; emission, 535 nm). At least 8 replicas were carried out 
or each condition. 
Superoxide anion production by dHL-60 cells was measured in 
 luminol oxidation assay using the Superoxide Anion Detection kit 
Calbiochem-Merck KGaA, Darmstadt, Germany). To measure the ef- 
ects of i 6 A on basal production, cells were pretreated with 10 or 100 μM i 6 A in complete medium or left untreated for 6 h, then cen- 
trifuged and resuspended in the superoxide anion assay medium, 
containing luminol and enhancer solutions. Chemiluminescence from 
luminol oxidation was kinetically measured on a Tecan Ultra multi- 
plate reader over 40 min. The same kit was used to measure the 
ability of i 6 A pretreatment to inhibit TPA-induced superoxide anion 
production. Brieﬂy, cells were pretreated with i 6 A (dose–response 
experiment: 0, 1, 10, or 100 μM i 6 A for 6 h; time-course experiment: 
10 μM i 6 A for 1, 2, 6, or 24 h), resuspended in assay medium, immedi- 
ately stimulated with 8 μM TPA and assessed for chemiluminescence. 
To test the effects of i 6 A analogs, cells were pretreated with 10 μM 
of each compound for 6 h before TPA addition, and chemilumines- 
cence was measured at 50–55 min. Each sample was read at least in 
triplicate and each experiment was carried out twice. Data were ex- 
pressed as the mean and standard error of the relative luminescence 
units (RLU) normalized to the mean value of each experiment. 
Mouse ear inﬂammatory model 
We developed a mouse model of TPA-induced inﬂammation using 
Car-S mice, genetically susceptible to inﬂammation and skin tumori- 
genesis [ 27 ]. In this model, mice ears are treated once with 1 μg TPA 
in 20 μl acetone to induce skin inﬂammatory response (i.e. tissue 
edema and inﬂammatory cells inﬁltration) and then evaluated 24 h 
later macro- and microscopically. We used this model to test the in 
vivo anti-inﬂammatory effects of i 6 A and benzyl 6 A. In detail, the outer 
surface of the right ear of Car-S mice ( n = 8 for each chemical) was 
pretreated with i 6 A or benzyl 6 A (10 mg / kg in 20 μl 95% ethanol), 24 
and 1 h before a single treatment with TPA. The left ear was pretreated 
at the same time points with only 95% ethanol before TPA treatment, 
as a positive control for the induction of the inﬂammatory response. 
For negative controls, 4 additional mice received 95% ethanol (left 
ear) or i 6 A (right ear) according to the experimental schedule, fol- 
lowed by a single treatment with acetone. Then, 24 h after TPA (or 
acetone) treatment, ears were macroscopically examined before the 
mice were sacriﬁced. Ears were removed and cut in two parts for 
histological and immunohistochemical analyses. 
For histological analysis, ears were ﬁxed in 10% buffered formalin, 
parafﬁn-embedded, sectioned and stained with hematoxylin-eosin. 
For immunohistochemical analysis, 3- μm thick sections were de- 
waxed, rehydrated, then incubated in 0.3% H 2 O 2 in methanol for 
30 min to inhibit endogenous peroxidase. After antigen unmasking, 
sections were incubated with rat anti-mouse lymphocyte antigen 6 
complex, locus G (Ly-6G) IgG (clone 1A8; 1:100; BD Biosciences, San 
Diego, USA) overnight at 4 ◦C. After incubation with biotinylated rab- 
bit anti-rat IgG (1:500; Abcam, Cambridge, UK) for 1 h at room tem- 
perature, avidin DH and biotinylated horseradish peroxidase H were 
added (the Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, 
USA), and staining was carried out using 3-amino-9-ethylcarbazole 
(AEC) substrate kit for peroxidase (Vector Laboratories). Stained in- 
ﬂammatory cells in the dermis were quantiﬁed by collecting three 
digital images per tissue slice (NIS-Elements F 3.2 software, Nikon 
Instruments) and counting using the imaging software NIS-Elements 
BR 4.00.05 (Nikon). 
Statistical analysis 
Differences in quantitative measures were assessed using analysis 
of variance followed by Tukey ’ s test for multiple comparison, when 
appropriate. Correlation between microarray gene expression data 
and real-time PCR results was calculated using Pearson ’ s test. Statis- 
tical tests were done using the Rcmdr package in R [ 28 ]. All P -values 
were two-sided. 
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Fig. 1. i 6 A and its analogs inhibited growth of MCF7 human breast adenocarcinoma 
cells. MCF7 cells were treated with a single dose of 10 μM i 6 A, allyl 6 A, benzyl 6 A or 
butyl 6 A in culture medium or left untreated for 4 days. Cell growth was measured 
with the AlamarBlue 
®
assay and expressed as relative ﬂuorescence units (RFU) at 
day 4 normalized to that at day 0. The line within each box represents the median 
ﬂuorescence value of 8 replicates; upper and lower edges of each box represent the 
75th and 25th percentile, respectively; upper and lower bars indicate the highest and 
lowest values less than one interquartile range from the extremes of the box. *** 
P < 0.0001 vs. untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Gene expression proﬁles of untreated MCF7 cells and of cells treated for 6 h 
with 10 μM i 6 A or with equi-effective concentrations of allyl 6 A, benzyl 6 A or butyl 6 A. 
(A) Unsupervised clustering of samples (four replicates each) based on the expression 
levels of 3286 genes (detection P -value < 0.05 and coefﬁcient of variation > 0.15) 
revealed two main branches separating untreated from treated samples. Among treated 
cells, those treated with i 6 A clustered in a single branch distinct from those treated with 
the other three compounds. (B) Heatmap, resulted from the class comparison analysis, 
showing the ﬁrst 49 most signiﬁcantly ( P < 1.0 × 10 −10 ) differentially expressed genes 
in treated versus untreated cells and the clustering of samples (on top of the heatmap) 
based on the expression of these 49 genes only. Gene expression levels are indicated by 
the color bar: green, low; red, high. (C) Venn diagram of the numbers of differentially 
expressed genes ( P < 1.0 × 10 −4 and ≥1.5-fold) in MCF7 cells treated with i 6 A or one 
of its analogs, each compared to untreated cells. Overall, 182 genes were modiﬁed by 
all four nucleosides. (D) Correlation between microarray and quantitative PCR data for 
9 genes measured under all ﬁve treatment conditions. Pearson ’ s r = 0.98, P < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results 
i 6 A and its analogs inhibit MCF7 cell growth and alter the expression 
levels of genes involved in the NRF2-mediated antioxidant response 
The nucleoside i 6 A and its analogs allyl 6 A, benzyl 6 A and butyl 6 A
(whose chemical structures are shown in Supplementary Fig. 1 ) sig-
niﬁcantly inhibited the growth of MCF7 human breast adenocarci-
noma cells when present in the culture medium at 10 μM for 4 days
( P < 0.0001, Fig. 1 ). Dose–response experiments indicated that the
concentrations of allyl 6 A, benzyl 6 A and butyl 6 A needed to inhibit
growth to approximately the same extent as 10 μM i 6 A were 67, 11
and 44 μM, respectively ( Supplementary Fig. 2 ). 
To investigate if i 6 A and its analogs inhibit cell growth by acting on
the same cellular pathway, we treated MCF7 cells for 6 h with equi-
effective concentrations of the nucleosides prior to extracting RNA
for microarray analysis. Gene expression proﬁles were obtained using
HumanHT-12 Expression BeadChips. Unsupervised clustering analy-
sis of the samples according to their gene expression proﬁles revealed
tight clustering of the untreated samples distinct from the treated
samples, indicating that treatment with i 6 A or any of its analogs al-
tered gene expression in MCF7 cells ( Fig. 2 A). Moreover, i 6 A-treated
samples clustered together, showing that they differ somewhat from
those treated with one of the other three compounds. Class compar-
ison analysis of untreated vs. nucleoside-treated samples identiﬁed
232 differentially expressed genes (255 probes whose ﬂuorescence
intensities differed among the two classes) at a nominal P -value
< 1.0 × 10 −7 level, including 49 that were signiﬁcant at nominal
P < 1.0 × 10 −10 ( Fig. 2 B); interestingly, the large majority (79%)
of the 232 differentially expressed genes were up-regulated. Class
comparison analyses were also done individually between untreated
samples and those treated with i 6 A, allyl 6 A, benzyl 6 A and butyl 6 A
( Fig. 2 C). This analysis identiﬁed 451, 629, 508 and 527 differentiallyexpressed genes, respectively, at nominal P < 1.0 × 10 −4 and show-
ing ≥1.5-fold change. Overall, 182 genes were modulated by all four
compounds, suggesting that the nucleosides affect common molec-
ular pathways. About 60% of the genes modulated by i 6 A were also
modulated by the other compounds. These data are consistent with
the unsupervised clustering of samples based on gene expression
proﬁles where all treated samples were grouped together. 
To validate the microarray results, we selected nine differentially
expressed genes ( ATF3 , CXCR7 , DNAJB9 , HBP1 , HMOX1 , IGDCC3 , OS-
GIN1 , PPP1R15A and PPP1R3C ) and used quantitative real-time PCR
(qPCR) to measure expression levels in untreated MCF7 cells and in
cells treated with one of the four nucleosides. According to the mi-
croarray results, many of the genes (with the exception of CXCR7 ,
IGDCC3 and PPP1R3C ) were up-regulated by the nucleoside treat-
ments, and these results were conﬁrmed by qPCR. Correlation analysis
comparing qPCR and microarray expression levels for these genes in
the different samples gave Pearson ’ s r = 0.98 ( P < 0.0001; Fig. 2 D),
indicating that the gene expression data were highly reliable. 
The lists of 451, 629, 508 and 527 genes that were differentially
expressed at the P < 1.0 × 10 −4 level and with a fold-change ≥1.5
were then analyzed for pathway enrichment using Ingenuity Path-
ways Analysis (IPA) software. This analysis indicated that, among
584 A. Dassano et al. / Redox Biology 2 (2014) 580–589 
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Fig. 3. i 6 A treatment of MCF7 cells induced the NRF2 pathway. MCF7 cells were tran- 
siently transfected with a reporter gene plasmid in which the ﬁreﬂy luciferase gene 
was under the control of a minimal CMV promoter containing multiple antioxidant 
response elements (AREs). After 24 h, cells were treated with 10 μM i 6 A for 6 h or 
left untreated. Fireﬂy luciferase activity was normalized to that of Renilla luciferase 
expressed constitutively from a control plasmid, to control for transfection efﬁciency. 
Values are mean and SE of six independent transfections. *** P < 0.0001 versus un- 
treated cells. 
 ll the pathways deﬁned in the IPA knowledge base, the “NRF2- 
ediated oxidative stress response” pathway was the most signif- 
cantly associated with all four gene datasets, with a Fisher ’ s exact 
 < 0.001 for all four compounds ( Table 1 ). After correction for mul- 
iple testing by the Benjamini–Hochberg method, signiﬁcance was 
aintained at P < 0.01 for three of four datasets. Individually, the 
ompounds altered the expression of 14–18 genes out of a total 
f 187 genes involved in this pathway; 11 genes were modulated 
y all four compounds. However, among these genes, NFE2L2, the 
ene coding for NRF2 protein, was not present although in allyl 6 A- 
reated cells it showed a statistically signiﬁcant differential expres- 
ion ( P < 1.0 × 10 −4 ). Nevertheless, by qPCR we measured the mRNA 
evels of NFE2L2 after treatment of MCF7 cells with all the four com- 
ounds and found that NFE2L2 expression was indeed signiﬁcantly 
nduced by all of them as compared to untreated MCF7 cells ( Table 
 ). 
For two additional pathways (“p53 signaling” and “glucocorticoid 
eceptor signaling”), gene expression was signiﬁcantly modulated by 
ll four compounds at the P < 0.05 and P < 0.001 levels, respectively, 
ut, after correction for multiple testing, signiﬁcance was lost for 
hree or two datasets, respectively; therefore, these pathways were 
ot further studied. 
Focusing on the NRF2-mediated oxidative stress response, path- 
ay analysis showed that i 6 A and its analogs had a prevalently up- 
egulatory effect, on genes both upstream and downstream of the 
ranscription factor NRF2, suggesting that these modiﬁed nucleo- 
ides trigger a cellular response to oxidative stress. As illustrated in 
upplementary Fig. 3 , this response begins with an external stimulus 
hat induces the intracellular production of reactive oxygen species 
ROS), which activate cytoplasmic kinases, causing the transcription 
actor NRF2 to migrate to the nucleus and activate genes necessary 
or cellular protection. The ﬁgure also shows the position of genes 
odulated by i 6 A. Among the genes downstream of NRF2 and whose 
ranscription depends on its activation by i 6 A treatment, some ( e.g. 
MOX1 , alias HO-1 ) encode antioxidant proteins that reduce oxidative 
amage. Additionally, i 6 A treatment up-regulated some chaper (e.g. 
ERPUD1 ) involved in the repair and removal of damaged proteins; 
his observation is in agreement with our previous ﬁndings suggest- 
ng a role of i 6 A in the unfolded protein response [ 11 ]. Based on these 
esults, we investigated the role of i 6 A and its analogs in the oxidative 
tress response mediated by the NRF2 pathway. 
 
6 A activates the NRF2 transcription factor and reduces cellular ROS 
evels 
NRF2 is a transcription factor that, in the presence of a cellular 
xidative stress, binds to antioxidant response elements (AREs) in 
he promoters of genes involved in the cellular defense against this 
tress [ 29 ]. To functionally validate the expression data, we used a 
eporter gene assay to determine if i 6 A treatment activates NRF2, 
aking it bind to promoters containing AREs. MCF7 cells were tran- 
iently transfected with a plasmid in which the luciferase reporter 
ene was controlled by a minimal CMV promoter containing multi- 
le AREs and then cells were treated with i 6 A. Luciferase activity in 
 
6 A-treated cells was about 4-fold higher than that in untreated cells 
 P < 0.0001; Fig. 3 ). This result provided functional conﬁrmation of 
he ﬁndings obtained from microarray analysis, supporting evidence 
hat i 6 A activates the NRF2 pathway. 
To further investigate the role of i 6 A in the oxidative stress re- 
ponse, we examined its effects on cellular ROS production. First, 
e considered the possibility that i 6 A induces oxidative stress, by 
timulating ROS production. MCF7 cells were therefore treated for 
 h with 1, 10, or 100 μM i 6 A or left untreated, and then labeled 
ith 2 ′ ,7 ′ -dichlorodihydroﬂuorescein diacetate (H 2 DCFDA), a precur- 
or molecule that in cells is cleaved by intracellular esterases and oxidized by ROS to form a ﬂuorescent indicator. Surprisingly, we ob- 
served that i 6 A did not cause oxidative stress, but, on the contrary, 
reduced the basal amount of cellular ROS in a dose-dependent manner 
( Fig. 4 A). 
To further investigate the role of i 6 A in ROS production, we 
tested its effects in a cellular model of H 2 O 2 -induced oxidative stress. 
MCF7 cells were pretreated for 6 h with 1, 10, or 100 μM i 6 A, or 
left untreated, then labeled with H 2 DFCDA, stimulated with 1 mM 
H 2 O 2 , and assayed for ROS production. In agreement with our results 
on basal ROS production ( Fig. 4 A), i 6 A treatment also reduced the 
amount of ROS produced in response to H 2 O 2 stimulation; this effect 
was both dose dependent ( P < 0.001, Fig. 4 B) and time dependent 
( P < 0.001, Fig. 4 C). Finally, H 2 O 2 -induced ROS production was also 
signiﬁcantly reduced in cells pretreated with equi-effective doses of 
allyl 6 A ( P < 0.01) and benzyl 6 A ( P < 0.05), but not with butyl 6 A
( P > 0.05, Fig. 4 D). These results suggest that i 6 A and its analogs acti- 
vate NRF2 signaling and, therefore, trigger a cellular response against 
oxidative stress, induced by H 2 O 2 . 
Then, we validated these results in another cellular model of ox- 
idative stress, namely the production of superoxide anion by human 
promyelocytic leukemia HL-60 cells in response to stimulation by 
TPA. For these experiments, we used HL-60 cells differentiated along 
the neutrophil lineage (dHL-60) because of their high capacity to pro- 
duce ROS [ 21 ]. First, to understand the extent to which the biological 
response to i 6 A was similar between the dHL-60 and MCF7 cell lines, 
we cultured dHL-60 cells in the presence or absence of 10 μM i 6 A 
for 6 h and then used qPCR to measure the expression levels of the 
same 10 genes tested in MCF7 cells. All 10 genes were upregulated 
by i 6 A treatment, with mean relative quantities ranging from 1.51–
386-fold higher than untreated cells ( Supplementary Table 2 ). This 
result indicates that there are some differences between this cell line 
and the MCF7 line (where three of these genes were down-regulated 
by i 6 A and its analogs); these differences may inﬂuence the effects of 
treatment with these compounds in these two cell lines. In any case, 
the NFE2L2 gene, the central gene of the NRF2 pathway, showed over- 
expression after treatment of both cell lines with i 6 A ( Supplementary 
Table 2 ). 
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Table 1 
Top enriched pathways, and genes belonging to them, modulated by i6A and its three analogs in MCF7 human breast adenocarcinoma cells. 
Ingenuity canonical 
pathway Nucleoside P -value a B-H P -value b Ratio c Genes 
NRF2-mediated 
oxidative stress 
response (187 genes) 
i6A 2.63E −06 8.51E −04 0.086 ATF4 , DNAJA4 , DNAJB1 (alias 
Hsp40 ), DNAJB6 , DNAJB9 , 
GCLC , GCLM , GPX2 , HERPUD1 , 
HMOX1 (alias HO-1 ), JUN , 
JUND , KEAP1 , MAFG , PIK3R1 , 
TXNRD1 (alias TRXR1 ) 
allyl6A 1.32E −05 4.57E −03 0.096 ATF4 , CREBBP , DNAJB6 , 
DNAJB9 , EIF2AK3 , ENC1 , 
GCLC , GCLM , GPX2 , HERPUD1 , 
HMOX1 , JUN , JUND , MAFG , 
NFE2L2 , PIK3CA , PIK3R1 , 
TXNRD1 
benzyl6A 3.80E −05 1.32E −02 0.080 ACTG2 , ATF4 , DNAJB1 , 
DNAJB6 , DNAJB9 , GCLC , 
GCLM , HMOX1 , JUN , JUNB , 
JUND , MAFG , PIK3CA , 
PIK3R1 , TXNRD1 
butyl6A 2.75E −04 0.0832 0.075 ATF4 , CREBBP , DNAJB6 , 
DNAJB9 , ENC1 , GCLC , GCLM , 
HERPUD1 , HMOX1 , JUN , 
JUND , MAFG , PIK3R1 , 
TXNRD1 
p53 signaling (95 genes) i6A 2.51E −04 0.0282 0.095 GADD45A , GNL3 , JUN , 
PIK3R1 , PMAIP1 , RPRM , 
SERPINB5 , TNFRSF10B , 
TP53BP2 
allyl6A 9.12E −03 0.223 0.084 ADCK3 , HIPK2 , JUN , PIK3CA , 
PIK3R1 , PMAIP1 , RPRM , 
SIRT1 
benzyl6A 2.24E −03 0.130 0.084 ADCK3 , APAF1 , GADD45A , 
JUN , PIK3CA , PIK3R1 , 
PMAIP1 , RPRM 
butyl6A 3.72E −02 0.402 0.063 GADD45A , JUN , PIK3R1 , 
PMAIP1 , RPRM , SIRT1 
Glucocorticoid receptor 
signaling (277 genes) 
i6A 2.63E −04 0.0282 0.058 ANXA1 , CDK7 , CEBPB , CREB1 , 
CREBZF , DUSP1 , GTF2B , 
HSPA1A / HSPA1B , HSPA1L , 
HSPA4 , HSPA6 , JUN , NFKBIE , 
PIK3R1 , PLAU , SOS1 
allyl6A 2.14E −04 0.0372 0.072 ANXA1 , CEBPB , CREB1 , 
CREBBP , DUSP1 , FOXO3 , 
GTF2B , HSPA1A / HSPA1B , 
HSPA4 , JUN , NFAT5 , NRIP1 , 
PIK3CA , PIK3R1 , PLAU , 
SMAD4 , TAF4 , TAF5 , TAF6L , 
TRAF6 
benzyl6A 7.94E −04 0.0741 0.058 CREB1 , CREBZF , DUSP1 , 
FOXO3 , GTF2B , GTF2H1 , 
HSPA1A / HSPA1B , HSPA4 , 
HSPA6 , JUN , NFAT5 , NRIP1 , 
PIK3CA , PIK3R1 , TAF10 , TAF5 
butyl6A 5.50E −04 0.0832 0.061 ANXA1 , CDK7 , CEBPB , CREB1 , 
CREBBP , CREBZF , DUSP1 , 
GTF2B , HSPA1A / HSPA1B , 
HSPA4 , JUN , NRIP1 , PIK3R1 , 
PLAU , TAF4B , TAF5 , TRAF6 
a 
Right-tailed Fisher ’ s exact test run in Ingenuity Pathway Analysis software. 
b 
Multiple testing correction with the Benjamini–Hochberg method run in Ingenuity Pathway Analysis software. 
c 
Ratio between the number of genes in the dataset ( i.e. genes whose expression level changed by ≥1.5 fold and at P < 1.0 × 10 −4 ) that map to the pathway and the total number 
of genes in the pathway.In bold are the down-regulated genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 Next, we measured the effects of i 6 A on superoxide anion produc-
tion by dHL-60 cells using a kinetic chemiluminescent assay ( Fig. 5 ).
In untreated cells the basal level of luminol oxidation was minimal,
but it was even lower in cells pretreated with i 6 A ( P < 0.0001, Fig. 5 A).
In cells stimulated with 8 μM TPA, the chemiluminescent signal in-
creased rapidly over time, while in cells that had been pretreated with
i 6 A the oxidation of luminol was reduced in both a dose-dependent( Fig. 5 B) and time-dependent ( Fig. 5 C) manner. Finally, in cells pre-
treated with i 6 A analogs (6 h at 10 μM), the TPA-induced superoxide
anion production at 50–55 min was signiﬁcantly ( P < 0.0001) re-
duced by benzyl 6 A and butyl 6 A, but not allyl 6 A ( Fig. 5 D). Therefore,
in dHL-60 cells, like in MCF7 cells, i 6 A and its analogs were able to
contrast oxidative stress induced, in this case, by a different chemical
agent, i.e. TPA. 
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Table 2 
NFE2L2 mRNA levels in MCF7 cells treated with the four compounds for 6 h, at equi- 
effective doses. 
Treatment NFE2L2 RQ (SE) a P -value b 
No 1.08 (0.060) 
Allyl6A 2.34 (0.063) < 0.001 
Benzyl6A 1.88 (0.083) < 0.001 
Butyl6A 1.83 (0.13) < 0.001 
i 6 A 2.12 (0.14) < 0.001 
a 
Relative quantity (RQ) mean value of four replicas. 
b 
Analysis of variance, followed by Tukey ’ s test for multiple comparisons, versus un- 
treated cells. 
Fig. 4. i 6 A inhibited ROS production in MCF7cells. (A) i 6 A reduced the basal production 
of reactive oxygen species (ROS) in a dose-dependent manner. Cells were treated with 
i 6 A for 6 h and then assayed for ROS production after labeling with H 2 DCFDA for 30 min. 
Data are shown as mean ﬂuorescence units ± SE. (B) i 6 A inhibited H 2 O 2 -induced 
production of ROS in a dose-dependent manner. Cells were treated with i 6 A for 6 h 
before being loaded with H 2 DCFDA (30 min), stimulated with 1 mM H 2 O 2 (15 min), and 
assayed for ROS production. Data are mean ﬂuorescence units ± SE. (C) i 6 A inhibited 
H 2 O 2 -induced ROS production in a time-dependent manner. Cells were treated with 
10 μM i 6 A for 1, 2, 6, 24 or 30 h before induction of ROS production with 1 mM H 2 O 2 as 
above. Data are mean ﬂuorescence units ± SE. (D) Equi-effective concentrations of i 6 A 
analogs also inhibit H 2 O 2 -induced ROS production. The line within each box represents 
the median ﬂuorescence value; upper and lower edges of each box represent the 75th 
and 25th percentile, respectively; upper and lower bars indicate the highest and lowest 
values less than one interquartile range from the extremes of the box. Control: H 2 O 2 - 
only-treated cells. * P < 0.05; ** P < 0.01; *** P < 0.001. At least 8 replicas were carried 
out for each condition. 
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Fig. 5. i 6 A inhibits superoxide anion production in dHL-60 cells. (A) Basal levels of 
superoxide anion production in dHL-60 cells are low and further reduced by treatment 
with 10 or 100 μM i 6 A for 6 h. Data are mean and SE. (B) i 6 A pretreatment inhibited TPA- 
induced superoxide anion production in a dose-dependent manner (1, 10, or 100 μM 
for 6 h before 8 μM TPA treatment). Data are mean and SE. (C) TPA-induced superoxide 
anion production was inhibited by pretreatment with 10 μM i 6 A in a time-dependent 
manner (1, 2, 6, or 24 h before TPA treatment). dHL-60 cells treated only with TPA were 
used as control. (D) Butyl 6 A and benzyl 6 A signiﬁcantly inhibit TPA-induced superoxide 
oxidative stress. Control: dHL-60 cells treated only with TPA. The line within each 
box represents the median luminescence value; upper and lower edges of each box 
represent the 75th and 25th percentile, respectively; upper and lower bars indicate the 
highest and lowest values less than one interquartile range from the extremes of the 
box. Normalized RLU: relative luminescence units normalized to the mean value of each 
experiment. Data are from at least 5 replicates, from two independent experiments. ** 
P < 0.01, *** P < 0.001. 
  
6 A and benzyl 6 A inhibit TPA-induced inﬂammation in vivo 
To determine if the observed inhibitory effects of i 6 A on ROS pro- 
uction in cellular models could be reproduced in vivo , we used a 
ouse model of TPA-induced oxidative stress leading to inﬂamma- 
ion. In particular, we measured the effects of i 6 A and benzyl 6 A pre- 
reatment on the inﬂammatory response to TPA in Car-S mice, a strain 
hat is genetically susceptible to inﬂammation and skin tumorigene- 
is [ 27 ]. In a split-body design, left ears served as the positive control 
roup (pretreated only with vehicle before TPA) while right ears were 
he experimental group (pretreated with i 6 A or benzyl 6 A before TPA). 
n the macroscopic examination 24 h after TPA treatment ( Fig. 6 A), 
he left ears of 16 Car-S mice showed a typical inﬂammatory status, 
haracterized by evident redness and tissue thickening. In contrast, 
he right ears of Car-S mice, pretreated with two doses of either i 6 A ( n = 8; one animal is shown in Fig. 6 A) or benzyl 6 A ( n = 8) before TPA
application, appeared macroscopically normal 24 h later. 
At the microscopic examination, the positive control group 
showed a massive presence of inﬂammatory cells inﬁltrating the der- 
mis together with increased vascular permeability and tissue edema 
( Fig. 6 B). The altered histology is clearly seen when compared to tissue 
slices from negative control animals pretreated with vehicle or with 
i 6 A without a successive TPA treatment ( Supplementary Fig. 4 A and 
B). In the i 6 A- and benzyl 6 A-pretreated groups ( Fig. 6 C and D, respec- 
tively), we observed an evident reduced presence of inﬂammatory 
cells inﬁltrating the dermis, although the effects of TPA on vascular 
permeability and tissue edema were still evident. In the positive con- 
trol and experimental groups, the inﬁltrating cells were classiﬁed as 
neutrophils, according to morphological criteria and immunostaining 
with an antibody against Ly-6G, an antigen expressed predominantly 
by peripheral neutrophils ( Fig. 6 F–H). Cell counting on three digital 
images per tissue slice revealed signiﬁcantly fewer neutrophils in the 
ear dermis of i 6 A- ( ˜ 50%) and benzyl 6 A-pretreated mice ( ˜ 28%) than in 
samples that were not pretreated ( Fig. 6 E, P < 0.0001). 
Discussion 
This study showed that i 6 A and its synthetic analogs allyl 6 A, 
benzyl 6 A and butyl 6 A all inhibit the growth of MCF7 human breast 
adenocarcinoma cells and modulate their transcription proﬁles, in 
particular, by altering the expression of genes involved in the response 
to oxidative stress. Additionally, we found that these chemicals signif- 
icantly reduced ROS production induced by two oxidants (H 2 O 2 and 
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Fig. 6. Topical application of i 6 A and benzyl 6 A reduced the inﬂammatory response 
to TPA treatment, on Car-S mice ears. (A) Photograph of one of the 8 Car-S mice 
pretreated twice on the right ear with i 6 A (in 95% ethanol) before a single treatment 
with TPA. The right ear appeared normal 24 h after TPA application, whereas the left 
ear, pretreated only with vehicle (ethanol) before TPA, showed a typical inﬂammatory 
status, characterized by evident redness and tissue thickening. (B) Hematoxylin-eosin 
staining of tissue slices from left ears (pretreated with ethanol alone before TPA) reveals 
massive inﬁltration of inﬂammatory cells in the dermal layer and tissue edema. (C, D) 
Stained tissue slices from right ears of mice pretreated with i 6 A (C) or benzyl 6 A (D) 
show a less severe inﬂammatory status caused by TPA application. (E) The number of 
inﬁltrating inﬂammatory cells, after TPA treatment, in i 6 A- and benzyl 6 A-pretreated 
ears was signiﬁcantly lower than in vehicle-pretreated ears. *** P < 0.0001. (F, G and H) 
Immunohistochemical staining with anti-Ly-6G IgG showed that the inﬁltrating cells, 
in vehicle-, i 6 A- and benzyl 6 A-pretreated ears, respectively, were neutrophils. Scale 
bar: 50 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TPA) in two cancer cell lines (MCF7 and dHL-60). Finally, we observed
that i 6 A or benzyl 6 A pretreatment had an anti-inﬂammatory effect in
vivo in a Car-S mouse model of TPA-induced inﬂammation. 
In MCF7 cells treated or not with i 6 A or its analogs, microarray
gene expression proﬁling revealed an overlapping pattern of differ-
entially expressed genes, with 182 genes modiﬁed by all four com-
pounds. Statistical analysis of the differentially expressed genes using
IPA software resulted in the identiﬁcation of the “NRF2-mediated ox-
idative stress response” pathway as most signiﬁcantly associated to
the lists of genes whose expression levels were signiﬁcantly modu-
lated by all four compounds. In the “NRF2-mediated oxidative stress
response” pathway, under oxidative stress conditions, the transcrip-
tion factor NRF2 (nuclear factor-erythroid 2-related factor 2) binds
to the antioxidant response elements (ARE) within the promoters of
genes that code for antioxidant proteins, activating their transcrip-
tion and thus initiating a cellular defense response to oxidative stress
(reviewed in [ 29 ]). This pathway is considered an important target for
cancer chemoprevention, since many natural antioxidant and poten-
tial chemopreventive agents (e.g. isothiocyanates, indoles, terpenesand phenolic compounds) reportedly induce NRF2 / ARE-dependent
gene expression (reviewed in [ 30 ]). Moreover, the NRF2 pathway
plays a relevant defensive role in pathologies such as chronic ob-
structive pulmonary disease, where its activation has been shown to
inhibit oxidative stress, endoplasmic reticulum stress, and inﬂamma-
tion [ 31 ]. 
Although i 6 A has been studied for many years for its possible
antineoplastic activity, we found here that it does not behave like
standard chemotherapeutic agents, whose inhibition of cancer cell
proliferation is associated with the generation of ROS and the con-
sequent induction of oxidative stress [ 32 –34 ]. In this study, i 6 A did
not stimulate basal ROS production and instead had inhibitory effects.
Moreover, i 6 A and one of its synthetic analogs, benzyl 6 A, had similar
inhibitory effects on the production of ROS induced by both H 2 O 2 and
TPA treatment in MCF7 and dHL-60 cells, respectively. Thus these two
molecules have particular interest as potential antioxidant agents. On
the other hand, allyl 6 A and butyl 6 A behaved differently in the two cel-
lular models: ally 6 A only reduced ROS production induced by H 2 O 2
in MCF7 cells, whereas butyl 6 A only inhibited TPA-induced oxida-
tive stress in dHL-60 cells. Additional studies are required to clarify
these differences and to understand whether there is any molecular
link between the anti-oxidant and antiproliferative effects of these
molecules. 
Considering the stimulating effects of i 6 A and its analogs on the
NRF2-mediated oxidative stress response, as shown here, we hypoth-
esize that these compounds act like dietary phytochemicals, non-
nutritive compounds of edible plants some of which are classiﬁed as
chemopreventive agents. Some phytochemicals block the initiation
of carcinogenesis by activating the NRF2-mediated antioxidant re-
sponse, and inhibit tumor progression via cell cycle arrest and induc-
tion of apoptosis after the activation of different cellular responses
(reviewed in [ 35 ]). These compounds, like i 6 A and its analogs, in-
duce detoxifying and antioxidant enzymes—such as heme oxygenase-
1 (encoded by HMOX1 ) and glutamate-cysteine ligase (GCLC)—that
protect cells against ROS and reactive metabolites of carcinogens,
thus preventing tumorigenesis. Additionally, chemopreventive phy-
tochemicals trigger several antineoplastic signaling pathways ( e.g. in-
duction of apoptosis via c-JUN NH 2 -terminal protein kinase signaling,
or blocking cell cycle by inhibition of NF- κB signaling), contrasting
cancer progression. Similarly, i 6 A has been reported to inhibit cell
cycle progression [ 11 , 14 , 15 ] and induce apoptosis through the inhi-
bition of NF- κB signaling [ 14 ]. It is interesting to note that i 6 A and its
analogs, in addition to their activation of the NRF2-mediated antiox-
idant response, also modulated genes in the p53 signaling pathway,
although at lower statistical signiﬁcance. Since the p53 pathway is
a master regulator of the cell cycle and of apoptosis [ 36 ], these ob-
servations provide some molecular insight into the antiproliferative
actions of these modiﬁed nucleosides. 
A recent paper showed that i 6 A speciﬁcally binds to the A3 adeno-
sine receptor [ 19 ]. The four known adenosine receptors, A(1)AR,
A(2A)AR, A(2B)AR and A(3)AR, play important roles in a large number
of biological pathways and are also involved in different physiological
and pathological conditions, such as cancer and inﬂammatory disease
[ 37 ]. Through A(3)AR, adenosine exerts an anti-inﬂammatory effect
on neutrophils by inhibiting superoxide production and chemotaxis
[ 38 ]. Various A(3)AR agonists have been investigated for their anti-
inﬂammatory effects in preclinical and clinical studies (reviewed in
[ 39 ]). Therefore, we hypothesize that the antioxidant effects of i 6 A
observed in our in vitro experiments and its activation of the NRF2
pathway, are also mediated by A(3)AR. The same may also be true
for benzyl 6 A which behaved similarly to i 6 A in our experiments,
while the divergent effects of ally 6 A and butyl 6 A may be mediated
by other receptors. Indeed, our transcriptome analysis suggested that
i 6 A and its analogs also modulated several genes belonging to the
“glucocorticoid receptor signaling” pathway which is known to ex-
ert anti-inﬂammatory effects [ 40 ], thus suggesting another possible
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Rolecular mechanism of action of these chemicals that needs further 
nvestigation. 
Possibly the most interesting result in the present study is the 
n vivo anti-inﬂammatory effect of i 6 A and benzyl 6 A when topi- 
ally applied to mouse ears before TPA treatment. To the best of 
ur knowledge, these anti-inﬂammatory properties have never been 
bserved before. Further studies are needed to determine if this in 
ivo activity is mediated by the NRF2 pathway. Some insight on this 
ossibility comes from studies using Nrf2-null mice, which devel- 
ped a lupus-like autoimmune syndrome characterized by multior- 
an inﬂammatory lesions [ 41 ]. Comparison of wild-type and Nrf2- 
ull mice showed that Nrf2 protects the liver from oxidative stress, 
NA damage and steatohepatitis induced by the tumor promoter 
,3,7,8-tetrachlorodibenzo-p-dioxin [ 42 ]. Moreover, UVB-irradiated 
rf2-null mice showed accelerated photoageing [ 43 ]. Altogether, 
hese results highlight the importance of the Nrf2 pathway in the 
n vivo anti-oxidant and anti-inﬂammatory responses to endogenous 
nd exogenous stimuli. 
In light of the observed in vivo anti-inﬂammatory effects in a 
ouse model exerted by i 6 A and benzyl 6 A and of their strong in 
itro antiproliferative effects and inhibition of ROS generation, future 
tudies should investigate these two agents for their possible topical 
se in humans. In particular, they might be an attractive approach to 
lleviate skin inﬂammation and oxidative stress-induced tissue dam- 
ge caused, for example, by UV radiation, or to prevent UV-related 
kin tumors. 
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